PDCD6IPP2

Across TCGA pan-cancer cohorts, PDCD6IPP2 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated PDCD6IPP2 data layer compared with 18 for mass-spec protein.

The strongest signal is observed in esophageal carcinoma (ESCA), where higher PDCD6IPP2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PDCD6IPP2 expression acts as an unfavorable survival marker.

ESCA and ACC are the cancer types where PDCD6IPP2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ESCA	OS	Median	All	0.179	0.704	<.001	15	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

PDCD6IPP2–ESCA (OS)

Open the ESCA breakdown →